Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.55 |
| ▸ | PI4KA | P42356 | 2/20 | 0.43 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.43 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.43 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5106466 | 0.83 | ADORA2A (0.71) | ADORA2AADORA3ADORA1ADORA2BPI4KA | |
| SCHEMBL31061139 | 0.77 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BPI4KA | |
| SCHEMBL26968390 | 0.74 | ADORA3 (0.65) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL26968445 | 0.74 | ADORA3 (0.66) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL18526490 | 0.73 | ADORA2A (0.69) | ADORA2AADORA3ADORA1ADORA2BPI4KA | |
| SCHEMBL7253894 | 0.73 | ADORA3 (1.00) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL1755068 | 0.71 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BPI4KA | |
| SCHEMBL13977903 | 0.70 | ADORA2A (0.69) | ADORA2AADORA3ADORA1ADORA2BPI4KA | |
| SCHEMBL20878863 | 0.70 | ADORA2A (0.72) | ADORA2AADORA3ADORA1ADORA2BHSP90B1 | |
| SCHEMBL29108594 | 0.69 | ADORA2A (0.56) | ADORA2AADORA1ADORA2BPI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4491645-A1 | CURABLE COMPOSITION, CURED PRODUCT, LAMINATE, AND PRODUCTION METHODS THEREOF | Mitsubishi Chemical Corporation (JP) | 2025-01-15 | — | — | EP | disclosed |
| WO-2023171067-A1 | CURABLE COMPOSITION, CURED PRODUCT, LAMINATE, AND PRODUCTION METHODS THEREOF | 三菱ケミカル株式会社 | 2023-09-14 | — | — | WO | disclosed |
| US-20220048884-A1 | NRF2 ACTIVATOR | BIOGEN MA INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048884-A1 | NRF2 ACTIVATOR | NFE2L2, KEAP1, NQO1 | ADORA2A 1615/4885ADORA3 3270/4885ADORA1 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.